Novo Nordisk A/S (NYSE:NVO) Stock Holdings Lifted by My Legacy Advisors LLC

My Legacy Advisors LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 2.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,029 shares of the company’s stock after purchasing an additional 201 shares during the period. My Legacy Advisors LLC’s holdings in Novo Nordisk A/S were worth $583,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA lifted its position in shares of Novo Nordisk A/S by 2.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 77,494 shares of the company’s stock worth $11,061,000 after buying an additional 1,860 shares during the last quarter. Hsbc Holdings PLC boosted its holdings in shares of Novo Nordisk A/S by 19.4% during the 2nd quarter. Hsbc Holdings PLC now owns 54,804 shares of the company’s stock worth $7,852,000 after buying an additional 8,922 shares during the period. Brighton Jones LLC boosted its holdings in shares of Novo Nordisk A/S by 62.9% during the 2nd quarter. Brighton Jones LLC now owns 14,570 shares of the company’s stock worth $2,080,000 after buying an additional 5,625 shares during the period. Ieq Capital LLC grew its stake in Novo Nordisk A/S by 0.4% in the 2nd quarter. Ieq Capital LLC now owns 34,404 shares of the company’s stock valued at $4,911,000 after buying an additional 128 shares during the last quarter. Finally, Benjamin Edwards Inc. increased its stake in shares of Novo Nordisk A/S by 2.6% in the second quarter. Benjamin Edwards Inc. now owns 3,455 shares of the company’s stock worth $493,000 after purchasing an additional 87 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BMO Capital Markets cut their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S presently has an average rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO opened at $78.74 on Friday. The stock has a market capitalization of $353.33 billion, a price-to-earnings ratio of 25.48, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The business’s fifty day moving average price is $97.76 and its two-hundred day moving average price is $117.23. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.